Technology

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Ted Sweetser discusses how the technology is providing greater insight into how marketing materials are being viewed.

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Ted Sweetser discusses how the technology is expanding the amount of content that can be created.

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

Davidi Vortman, CEO, UltraSight, discusses how AI-powered heart scan technology can help high-risk cardiovascular disease patients.

As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.

Hyfe’s CEO discusses the importance of DTx and how it can change the way certain conditions are treated.

Marcel Botha, CEO of 10XBeta, identifies the most significant technological innovations in medical device manufacturing that will be crucial for future pandemic preparedness and supply chain stability.

Matthew Yelovich, partner at Cleary Gottlieb, discusses his transition in late-2024 from working as a federal prosecutor to a role at Cleary Gottlieb, as well as how he sees the intersection of technology and law evolving in the Bay Area.

Matthew Yelovich, partner at Cleary Gottlieb, discusses some of the broader implications for corporate governance and accountability the Theranos case highlights.

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.

If used properly, AI can be a game-changer for drug development.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Jennifer Kyle, CEO and founder of Condor, explores how improving financial management directly impacts drug pricing.

In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.

As coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.

Making early commercial data and analytics decisions for launch cen future-proof their data management.

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship with patients and new technology.

Heather Gervais, CEO of Osso VR, discusses how technological advancements in VR are solving problems for pharmaceutical sales reps.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

The CEO discusses his company’s platform that helps reformulate oral solid dose medications to liquid forms.